FEM1B Antibody

What is FEM1B and why is it important in research?

FEM1B is a protein homologous to the C. elegans FEM-1 sex determination protein. It contains a VHL-box motif that mediates interactions with certain E3 ubiquitin ligase complexes and functions as a substrate recognition subunit (SRS). In mammalian systems, FEM1B plays critical roles in several cellular processes including:

• Regulation of Gli transcription factors in the Hedgehog signaling pathway

• Glucose homeostasis and pancreatic islet function

• Apoptotic pathways through association with death receptors Fas and TNFR1

FEM1B has gained significant research interest due to its involvement in these diverse biological processes and potential implications in diseases like cancer and diabetes . Its role in protein degradation pathways has also made it an attractive target for therapeutic development, particularly in targeted protein degradation approaches .

What epitopes do commonly available FEM1B antibodies recognize?

Most commercially available FEM1B antibodies target the C-terminal region of the protein. For example:

• Rabbit polyclonal antibody Li-51 is directed against a C-terminal epitope of mouse FEM1B with the sequence C-RANDINYQDQIPRTLEEFVGFH

• Commercial polyclonal antibody 19544-1-AP recognizes the C-terminus of FEM1B

• Goat polyclonal antibody ab801 targets the FEM1B C-terminus

The C-terminal region is often selected for antibody generation because it contains sequences that are more likely to be surface-exposed and immunogenic, while also being distinctive from related proteins, helping to ensure specificity.

What tissue and cell types express FEM1B?

FEM1B is expressed in various human and mouse tissues. Notable expression patterns include:

• Pancreatic islets, including both β-cells and non-β cells

• High expression in INS-1E cells, a pancreatic β-cell line

• Expression in colon cancer cell lines such as SW480

• Detected in HEK293T cells, where it can be targeted for protein degradation applications

Studies with FEM1B knockout mice have demonstrated its importance in pancreatic islet function, specifically in glucose-stimulated insulin secretion . When designing experiments, researchers should consider these expression patterns to select appropriate cellular models.

What are the optimal conditions for Western blotting with FEM1B antibodies?

When performing Western blot analysis with FEM1B antibodies, consider the following methodological guidelines:

• Sample preparation: FEM1B is approximately 70 kDa. Use standard SDS-PAGE with 8-10% polyacrylamide gels for optimal resolution.

• Transfer conditions: Transfer proteins to PVDF or nitrocellulose membranes using standard wet or semi-dry transfer protocols (25V for 1.5 hours for wet transfer).

• Blocking: Block membranes with 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute FEM1B antibodies (such as Li-51 or 19544-1-AP) at 1:1000 to 1:5000 in blocking buffer. Incubate overnight at 4°C with gentle rocking.

• Detection: Use appropriate HRP-conjugated secondary antibodies and enhanced chemiluminescence for detection.

When troubleshooting, consider that the C-terminal nature of most FEM1B antibodies may result in reduced binding if the protein undergoes C-terminal processing or if this region is obscured in protein complexes .

How can I optimize immunoprecipitation protocols with FEM1B antibodies?

For successful immunoprecipitation (IP) of FEM1B or FEM1B-interacting proteins:

• Lysis buffer recommendation: Use NP-40 or RIPA buffer containing protease inhibitors. For detecting ubiquitylation, include deubiquitinase inhibitors like N-ethylmaleimide (NEM).

• Pre-clearing: Pre-clear lysates with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody immobilization: Conjugate purified FEM1B antibody to Protein A/G beads (approximately 2-5 μg antibody per IP reaction).

• Incubation conditions: Incubate lysates with antibody-conjugated beads overnight at 4°C with gentle rotation.

• Washing: Perform at least 3-5 washes with lysis buffer to reduce background.

When studying FEM1B interactions with Gli1 or other binding partners, co-immunoprecipitation experiments have been successfully performed using this approach, as demonstrated in studies where immunoprecipitation of Myc-Gli1 co-immunoprecipitated HA-Fem1b from co-transfected 293T cell lysates .

What controls should be included when validating FEM1B antibody specificity?

Proper validation of FEM1B antibodies requires several controls:

• Positive control: Lysate from cells known to express FEM1B (e.g., INS-1E pancreatic β-cells or HEK293T cells with overexpressed FEM1B).

• Negative control: Lysate from FEM1B knockout cells or cells where FEM1B expression has been silenced using siRNA/shRNA.

• Peptide competition: Pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce the signal.

• Recombinant protein: Purified recombinant FEM1B protein can serve as a positive control and for antibody titration.

• Cross-reactivity assessment: Test the antibody against related proteins (other FEM family members) to ensure specificity.

Researchers have successfully validated FEM1B antibodies using FEM1B knockout mice tissues compared to wild-type tissues, demonstrating the importance of genetic controls in antibody validation .

How can FEM1B antibodies be used to study its role in the ubiquitin-proteasome pathway?

FEM1B functions as a substrate recognition subunit within E3 ubiquitin ligase complexes. To study this function:

• Ubiquitylation assays: Perform in vitro or in vivo ubiquitylation assays using immunoprecipitation with FEM1B antibodies followed by Western blotting with ubiquitin antibodies.

• Substrate identification: Use FEM1B antibodies for immunoprecipitation followed by mass spectrometry to identify novel substrates.

• Mutational analysis: Generate FEM1B mutants (particularly targeting the VHL-box motif) and use antibodies to assess how these mutations affect substrate interaction and ubiquitylation.

• Proteasome inhibition: Combine treatment with proteasome inhibitors (e.g., MG132) and FEM1B immunoprecipitation to trap and identify ubiquitylated substrates.

Studies have demonstrated that Fem1b promotes the ubiquitylation of Gli1, and this function is dependent on its VHL-box motif. This was demonstrated through ubiquitylation assays where the VHL-box mutant (L597A) failed to promote Gli1 ubiquitylation compared to wild-type Fem1b .

What approaches can be used to study FEM1B-mediated targeted protein degradation?

The development of covalent FEM1B recruiters for targeted protein degradation has opened new research avenues:

• PROTAC development: FEM1B-based PROTACs can be designed by linking FEM1B-binding molecules (e.g., EN106) to ligands for proteins of interest.

• Validation experiments: Use FEM1B antibodies to confirm the mechanism of degradation through:

  • Western blotting to monitor protein levels

  • Co-immunoprecipitation to confirm FEM1B-substrate interaction

  • Proteomic analysis to assess selectivity

• Control experiments:

  • Use FEM1B knockout cells to confirm FEM1B-dependence

  • Test degradation kinetics with pulse-chase experiments

  • Compare with other E3 ligase-based degraders

Research has demonstrated that a PROTAC linking the FEM1B recruiter EN106 to JQ1 (a BET Bromodomain inhibitor) led to the degradation of BRD4, and this degradation was attenuated in FEM1B knockout cells. Similar approach with dasatinib led to BCR-ABL degradation in K562 leukemia cells .

How can I use FEM1B antibodies in studying its role in pancreatic β-cell function?

FEM1B plays a critical role in pancreatic islet function and glucose homeostasis:

• Immunohistochemistry protocol for pancreatic tissue:

  • Fix pancreatic tissue with S.T.F. fixative

  • Embed in paraffin and section at 5 μm

  • Perform antigen retrieval (citrate buffer, pH 6.0)

  • Block with 5% normal serum

  • Incubate with FEM1B antibody (1:100-1:500 dilution)

  • Use fluorescent or enzymatic detection systems

• Co-localization studies:

  • Perform double immunostaining with FEM1B antibodies and cell-type specific markers:

    • Insulin (β-cells)

    • Glucagon (α-cells)

    • Somatostatin (δ-cells)

    • Pancreatic polypeptide (PP cells)

• Functional studies:

  • Compare wild-type and FEM1B knockout islets

  • Assess glucose-stimulated and arginine-stimulated insulin secretion

  • Measure calcium signaling in response to glucose

Studies with FEM1B knockout mice have revealed abnormal glucose tolerance due predominantly to defective glucose-stimulated insulin secretion, highlighting the importance of FEM1B in β-cell function .

What factors might affect FEM1B antibody performance in immunofluorescence studies?

When performing immunofluorescence with FEM1B antibodies, consider these potential issues:

• Fixation sensitivity: Test multiple fixation methods (4% paraformaldehyde, methanol, or acetone) as the C-terminal epitopes recognized by many FEM1B antibodies may be sensitive to certain fixatives.

• Antigen retrieval: C-terminal epitopes may require antigen retrieval. Try citrate buffer (pH 6.0) or EDTA buffer (pH 8.0) heated to 95-100°C for 10-20 minutes.

• Permeabilization: Optimize permeabilization conditions (0.1-0.5% Triton X-100 or 0.1-0.5% saponin) to ensure antibody access to intracellular FEM1B.

• Antibody concentration: Titrate antibody concentrations (typically starting at 1:100-1:500) to find the optimal signal-to-noise ratio.

• Background reduction: Use appropriate blocking (5-10% normal serum from the species of the secondary antibody) and include 0.1-0.3% Tween-20 in wash buffers.

Proper controls, including FEM1B knockout tissues or peptide competition, are essential for validating immunofluorescence results, particularly when studying the subcellular localization of FEM1B in different cell types .

How can I troubleshoot high background or non-specific binding with FEM1B antibodies?

If experiencing high background or non-specific binding:

• Antibody dilution: Increase the dilution of primary antibody (test a range from 1:500 to 1:5000).

• Blocking optimization:

  • Extend blocking time (2-3 hours at room temperature)

  • Try different blocking agents (5% milk, 3-5% BSA, commercial blocking buffers)

  • Add 0.1-0.5% Tween-20 to blocking buffer

• Washing steps:

  • Increase number (5-6 washes) and duration (10 minutes each) of washing steps

  • Use TBS-T with 0.1-0.3% Tween-20

• Cross-adsorbed secondary antibodies: Use highly cross-adsorbed secondary antibodies to minimize cross-reactivity.

• Filter lysates: Centrifuge lysates at high speed (>14,000 g) or filter through 0.45 μm filters to remove particulates that might cause non-specific binding.

Non-specific binding can be particularly problematic when studying FEM1B in tissues with high autofluorescence, such as pancreatic tissue, where FEM1B has important functional roles .

How should I interpret discrepancies in FEM1B detection between different antibodies?

When facing discrepancies between different FEM1B antibodies:

• Epitope differences: Different antibodies targeting distinct epitopes may yield varying results due to:

  • Post-translational modifications masking certain epitopes

  • Conformational changes in protein structure

  • Protein-protein interactions blocking specific epitopes

• Isoform specificity: Confirm whether the antibodies recognize all known FEM1B isoforms or are specific to certain variants.

• Species reactivity: Ensure that antibodies are tested in the appropriate species; sequence variations between human, mouse, and rat FEM1B might affect antibody recognition.

• Validation approaches:

  • Use multiple antibodies targeting different epitopes

  • Perform knockdown/knockout validation with all antibodies

  • Use recombinant protein expression systems

• Technical factors: Consider differences in sample preparation, detection methods, and antibody quality/batch variation.

What considerations are important when using FEM1B antibodies to study its protein interactions?

When investigating FEM1B protein interactions:

• Experimental conditions that preserve interactions:

  • Use mild lysis buffers (e.g., NP-40 buffer with 150mM NaCl)

  • Include protease and phosphatase inhibitors

  • Consider crosslinking approaches for transient interactions

• Domain-specific considerations:

  • FEM1B contains ankyrin repeat domains and a VHL-box motif

  • The N-terminal ankyrin repeat domain and central kinesin light chain-like region mediate interaction with Gli1

  • The VHL-box motif (L597 is critical) is required for interaction with ubiquitin ligase components

• Control experiments:

  • Include negative controls (IgG, empty vectors)

  • Use mutant constructs to validate specific interaction domains

  • Perform reciprocal co-immunoprecipitations

• Validation approaches:

  • Complement co-IP with GST pull-down assays

  • Use proximity ligation assays for in situ detection

  • Consider bimolecular fluorescence complementation

Studies have demonstrated that FEM1B interacts with Gli1 through its N-terminal ankyrin repeat domain and central region, while its VHL-box motif mediates interaction with E3 ligase components. These interactions were validated through multiple approaches including co-immunoprecipitation and GST pull-down experiments .

What emerging applications of FEM1B antibodies should researchers consider?

As FEM1B research advances, several emerging applications of FEM1B antibodies show promise:

• Targeted protein degradation: The discovery of covalent FEM1B recruiters like EN106 opens opportunities for developing novel PROTACs. FEM1B antibodies will be crucial for validating degradation mechanisms and optimizing degrader designs.

• Biomarker development: FEM1B's roles in cancer and metabolic regulation suggest potential as a biomarker. Antibody-based assays could be developed for diagnostic or prognostic applications.

• Structural biology: FEM1B antibodies can facilitate protein purification for structural studies, potentially revealing novel insights into substrate recognition mechanisms.

• Single-cell analysis: Combining FEM1B antibodies with single-cell technologies could reveal cell-type specific functions and heterogeneity in expression and activity.

• Therapeutic target validation: As FEM1B emerges as a potential therapeutic target, antibodies will be essential for target validation studies and mechanism-of-action investigations.

Research has demonstrated that FEM1B-based degraders can effectively target proteins like BRD4 and BCR-ABL for degradation, suggesting broad potential in therapeutic applications across various disease contexts .

What methodological advances are improving FEM1B antibody applications?

Recent methodological advances enhancing FEM1B antibody applications include:

• Proximity-based labeling: BioID or APEX2 fused to FEM1B can identify proximal proteins in living cells, complementing traditional antibody-based interaction studies.

• Quantitative proteomic approaches: Combining FEM1B antibodies with advanced mass spectrometry enables identification of:

  • FEM1B interaction networks

  • Substrates targeted for ubiquitylation

  • Changes in protein abundance upon FEM1B manipulation

• CRISPR-based validation: CRISPR/Cas9 generated FEM1B knockout cells provide definitive controls for antibody specificity validation.

• Super-resolution microscopy: Advanced imaging techniques combined with highly specific FEM1B antibodies allow precise subcellular localization studies.

• Chemoproteomics: Covalent ligand screening approaches, as demonstrated with the discovery of EN106, provide new tools for studying FEM1B function and developing novel applications.